Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection

This publication has 14 references indexed in Scilit:

• A Randomized, Double-blind Trial Comparing Combinations of Nevirapine, Didanosine, and Zidovudine for HIV-Infected Patients
  JAMA, 1998
• Visceral abdominal-fat accumulation associated with use of indinavir
  The Lancet, 1998
• Chemotherapeutic agents for human immunodeficiency virus infection: mechanism of action, pharmacokinetics, metabolism, and adverse reactions
  Clinical Therapeutics, 1998
• Combination Treatment with Zidovudine, Didanosine, and Nevirapine in Infants with Human Immunodeficiency Virus Type 1 Infection
  New England Journal of Medicine, 1997
• Protease inhibitors: a therapeutic breakthrough for the treatment of patients with human immunodeficiency virus
  Clinical Therapeutics, 1997
• Drug Evaluations Anti-infectives: Nevirapine: A review of its development, pharmacological profile and potential for clinical use
  Expert Opinion on Investigational Drugs, 1996
• Nevirapine, Zidovudine, and Didanosine Compared with Zidovudine and Didanosine in Patients with HIV-1 Infection
  Annals of Internal Medicine, 1996
• Evaluation of Safety and Efficacy of 3TC (Lamivudine) in Patients with Asymptomatic or Mildly Symptomatic Human Immunodeficiency Virus Infection: A Phase I/II Study
  The Journal of Infectious Diseases, 1995
• Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitors
  Antimicrobial Agents and Chemotherapy, 1993
• Crystal Structure at 3.5 Å Resolution of HIV-1 Reverse Transcriptase Complexed with an Inhibitor
  Science, 1992